Table 1.
Characteristics of the Study Sample
| Characteristic | N | % |
|---|---|---|
| Age (years) (N = 479) | ||
| 16–25 | 192 | 40.3 |
| 26–35 | 190 | 39.7 |
| 36–45 | 62 | 12.9 |
| 46–55 | 25 | 5.2 |
| 56–65 | 9 | 1.9 |
| 66–75 | 1 | 0.2 |
| Limited gender category (N = 486) | ||
| Man/trans man | 373 | 76.8 |
| Nonbinary | 113 | 23.3 |
| Testosterone formulation (N = 486)a | ||
| Testosterone undecanoate (Reandron) | 358 | 73.7 |
| Testosterone enanthate (Primoteston depot) | 38 | 7.8 |
| Testosterone esters (Sustanon 250) | 10 | 2.1 |
| Testosterone 1% gel (Testogel) | 62 | 12.8 |
| Testosterone 2% gel (Testavan) | 10 | 2.1 |
| Testosterone 5% cream (Androforte 5) | 11 | 2.3 |
| Testosterone 2% cream (Androforte 2) | 1 | 0.2 |
| Other | 3 | 0.6 |
| Consistency of testosterone use (N = 485) | ||
| Consistent use since starting | 426 | 87.8 |
| Regularly stop and start use | 10 | 2.1 |
| Other (e.g., change in dosage or formulation) | 46 | 9.5 |
| Unsure/prefer not to say | 3 | 0.6 |
a
Multiple responses allowed for this question so total responses do not sum to 100%.